Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion With Water.

Trial Profile

Bioequivalence Study of YM060 Orally-disintegrating Tablet and Conventional Tablet - Ingestion With Water.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2011

At a glance

  • Drugs Ramosetron (Primary)
  • Indications Irritable bowel syndrome; Nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 11 Oct 2011 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top